MethylGene Presents MGCD290 Data at the 2012 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Fluconazole is the most widely used triazole antifungal, and previous in vitro and in vivo studies have established that MGCD290 enhances the antifungal activity of fluconazole, broadening its spectrum of activity and increasing the sensitivity of fungi to fluconazole.
Today’s poster details how, under different dosing schedules in a mouse model of systemic candidiasis, the combination of MGCD290 plus fluconazole significantly decreased the fungal kidney burden versus fluconazole alone. The combination of MGCD290 plus fluconazole was superior in both fluconazole-sensitive candidiasis and fluconazole-resistant candidiasis. Dosing schedules tested included a single dose of fluconazole plus MGCD290 administered after infection, or prophylactic dosing followed by a second post-infection treatment.
“The preclinical data reported today demonstrates the activity of MGCD290 under conditions relevant to mucosal and life-threatening systemic antifungal indications, as well as supporting the ability of MGCD290 to overcome azole resistance, an increasing problem.” said Dr. Jeffrey Besterman, MethylGene’s Executive Vice President, Research and Development and Chief Scientific Officer.
Enrollment in MethylGene’s randomized, multicenter, blinded, placebo-controlled, Phase II trial in the U.S. is over 50% complete. This study is evaluating MGCD290 plus fluconazole versus fluconazole alone in patients with moderate to severe vulvovaginal candidiasis (VVC), a form of yeast infection for which current treatments have limited efficacy. Topline data from this trial is expected around the end of 2012.
MGCD290 Investor Event
MethylGene will host an investor event focused on trends in fungal disease and the novel antifungal therapeutic, MGCD290, on Wednesday, October 10th, 2012 at 8.00-10.00 a.m. in New York, New York. The event will also be available by live webcast.
About MGCD290
MGCD290 is a first-in-class, orally available, small molecule inhibitor of the fungal enzyme Hos2. Current antifungal therapies suffer from a number of shortcomings including gaps in the coverage of fungal pathogens, acquisition of resistance, toxicity and drug-drug interactions. MGCD290 is initially being developed as a combination product with fluconazole, the most widely used triazole antifungal. In vitro, MGCD290 in combination with fluconazole reverses fluconazole resistance (primary and acquired) in a wide range of fungal species, including Candida glabrata. MGCD290 has completed multiple Phase I studies in healthy adult volunteers and has shown an excellent safety profile without drug-drug interactions, either as monotherapy or in combination with fluconazole. A randomized, controlled Phase II study in moderate to severe VVC is underway.
About MethylGene
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase II trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase I/II clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.
Investor Relations Contact:
Joseph Walewicz, CFA
Vice President, Business & Corporate Development
MethylGene Inc.
Phone: 514-337-3333 ext. 373
ir@methylgene.com
www.methylgene.com
Thomas Hoffmann
Vice President
The Trout Group LLC
Phone: 646-378-2931
thoffmann@troutgroup.com
www.troutgroup.com